MDMA for PTSD: FDA delays approval, seeks more data
In a surprising turn of events, the U.S. Food and Drug Administration (FDA) has decided not to approve MDMA-assisted therapy for post-traumatic stress disorder (PTSD) at this time. This decision comes as a setback for many who were hopeful about this innovative treatment approach. The FDA's decision...